Therapure Biomanufacturing announced approval for the manufacturing of partner Insmed’s ARIKAYCE® at its Mississauga facility by the U.S. FDA. ARIKAYCE is the first and only treatment approved by the FDA specifically for patients with Mycobacterium avium complex lung disease, a chronic and debilitating condition that can significantly increase patient morbidity and mortality.